Health and Fitness Health and Fitness
Tue, July 10, 2012
Mon, July 9, 2012
Fri, July 6, 2012
Thu, July 5, 2012
Wed, July 4, 2012
[ Wed, Jul 04th 2012 ] - Market Wire
Warnex Announces Refinancing
Tue, July 3, 2012
Mon, July 2, 2012
Sun, July 1, 2012
Fri, June 29, 2012
Thu, June 28, 2012
Wed, June 27, 2012
Tue, June 26, 2012
Mon, June 25, 2012
[ Mon, Jun 25th 2012 ] - Market Wire
Myths or Factsa" Campaign
Sun, June 24, 2012
Sat, June 23, 2012
Fri, June 22, 2012
Thu, June 21, 2012
Wed, June 20, 2012
Tue, June 19, 2012
Mon, June 18, 2012

AcelRx Pharmaceuticals to Present at the JMP Securities Healthcare Conference 2012


//health-fitness.news-articles.net/content/2012/ .. e-jmp-securities-healthcare-conference-2012.html
Published in Health and Fitness on Thursday, June 28th 2012 at 4:47 GMT by Market Wire   Print publication without navigation


AcelRx Pharmaceuticals to Present at the JMP Securities Healthcare Conference 2012 -- REDWOOD CITY, Calif., June 28, 2012 /PRNewswire/ --

AcelRx Pharmaceuticals to Present at the JMP Securities Healthcare Conference 2012

[ ]

REDWOOD CITY, Calif., June 28, 2012 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: [ ACRX ]), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that Richard King, President and Chief Executive Officer, will present at JMP Securities Healthcare Conference 2012 in New York City at The Peninsula New York Hotel.  The presentation is scheduled for Thursday, July 12, 2012 at 4:00 p.m. ET.

The presentation will be webcast live and can be accessed through: [ http://wsw.com/webcast/jmp18/acrx/ ].  For those who are not available to listen to the live broadcast, the presentation will be archived and available through [ http://www.acelrx.com ].

About AcelRx Pharmaceuticals, Inc.
AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain.  AcelRx's lead product candidate, the ARX-01 Sufentanil NanoTab PCA System, which is currently in Phase 3 clinical development, is designed to solve the problems associated with post-operative intravenous patient-controlled analgesia which has been shown to cause harm to patients following surgery because of the side effects of morphine, the invasive intravenous route of delivery and the inherent potential for programming and delivery errors associated with the complexity of infusion pumps.  AcelRx has two additional product candidates which have completed Phase 2 clinical development: ARX-02 for the treatment of cancer breakthrough pain, and ARX-03 for mild sedation, anxiety reduction and pain relief for patients undergoing painful procedures in a physician's office.  A fourth product candidate, ARX-04, is a sufentanil product for the treatment of moderate-to-severe acute pain, and AcelRx plans to initiate a Phase 2 study funded by a grant from USAMRMC, contingent on approval of the proposed clinical protocol for the study by USAMRMC.  For additional information about AcelRx's clinical programs please visit [ http://www.acelrx.com ]. 

SOURCE AcelRx Pharmaceuticals, Inc.

[ Back to top ]

RELATED LINKS
[ http://www.acelrx.com ]


Publication Contributing Sources